Skip to main content

Table 1 Baseline characteristics of CHC patients

From: Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy

Characteristics

Total population (n = 80)

Age (years)

57.7 ± 10.5

Sex: male, n (%)

42 (52.5)

Body mass index (kg/m2)

24.4 ± 3.5

Naïve cases, n (%)

42 (52.5)

Cirrhosis, n (%)

63 (78.8)

 Child–Pugh class A

58 (72.5)

 Child–Pugh class B

5 (6.3)

Liver stiffness (kPa)a

19.2 ± 15.3

HCV viral load (log IU/mL)

6.1 ± 0.7

Genotype, n (%)

 

 1

44 (55.0)

 3

30 (37.5)

 6

6 (7.5)

Alanine aminotransferase level (U/L)

80.0 ± 53.3

Treatment regimen, n (%)b

 

 SOF/DAC

22 (27.5)

 SOF/LED

8 (10.0)

 SOF/VEL

1 (1.25)

 SOF/DAC/RBV

42 (52.5)

 SOF/LED/RBV

6 (7.5)

 SOF/VEL/RBV

1 (1.25)

Sustained virological response, n (%)

80 (100)

  1. an = 49
  2. bDAC, daclatasvir; LED, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir